센티바이오사이언시즈(SNTI)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.45 (+16.93%), 시가총액 $0.03B, 52주 범위 $0.77 ~ $3.84.
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protectiv
센티바이오사이언시즈의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
센티바이오사이언시즈의 현재 주가는 $0.45 (+16.93%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
센티바이오사이언시즈의 시가총액은 약 $0.03B입니다.
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable dis